Atopic Dermatitis, Access and Reimbursement, EU5
Publish Date: June 6, 2017
Atopic Dermatitis Access & Reimbursement provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so drug manufacturers can build their market access strategy and optimize brand positioning.
- What are current prescribing practices for atopic dermatitis in the EU5, and how, if at all, are these impacted by payer policy?
- To what extent are off-label conventional systemics such as methotrexate and off-label biologics like Novartis’ Xolair (omalizumab) used for moderate to severe atopic dermatitis? How do payers cover any such off-label prescribing?
- What are payer and physician perspectives on promising but costly emerging agents such as Sanofi/Regeneron’s dupilumab?
- What key market access challenges will manufacturers of novel atopic dermatitis therapies face? What can they do to encourage optimal pricing and reimbursement terms and to drive uptake?